Pfizer Inc. (PFE)

US — Healthcare Sector
Peers: GILD  SNY  AMGN  GSK  BMY  SYK  MRK  BSX  NVO  DHR 

Automate Your Wheel Strategy on PFE

With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
PFE
Published: February 03, 2026 by: CNBC
Sentiment: Positive

Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.

Read More
image for news Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.
PFE
Published: February 03, 2026 by: Barrons
Sentiment: Negative

Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.

Read More
image for news Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
PFE
Published: February 03, 2026 by: CNBC
Sentiment: Neutral

Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Read More
image for news Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial
PFE
Published: February 03, 2026 by: Reuters
Sentiment: Positive

Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial.

Read More
image for news Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
PFE
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--PFE Q4 2025 Earnings Release.

Read More
image for news Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
PFE
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study had two objectives: (1) to demonstrate PF'3944 could achieve continued weight loss when switching from weekly to monthly subcutaneous injections and maintain its e.

Read More
image for news Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
BMY, LLY, MRK, NVO, PFE
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral

As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.

Read More
image for news What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
PFE
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
PFE
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Neutral

Pfizer PFE is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for sales and earnings for the fourth quarter is pegged at $16.93 billion and 57 cents per share, respectively.

Read More
image for news Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
PFE
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Neutral

Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Read More
image for news Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
PFE
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Negative

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)
PFE
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive

Pfizer (PFE) remains a 'Buy' ahead of its fiscal Q1 2027 earnings, with the stock deeply discounted and consensus estimates overly pessimistic. LOE headwinds are significant but phased, while cost savings ($7.7B by 2027) and pipeline catalysts offer margin and revenue offsets. Pipeline momentum—especially in obesity, oncology, and vaccines—could drive narrative shifts and repricing if key 2026 readouts succeed.

Read More
image for news Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)
Novavax Stock Pops After Pfizer Licensing Agreement
NVAX, PFE
Published: January 20, 2026 by: Schaeffers Research
Sentiment: Positive

Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing agreement -- worth up to $500 million, including a $30 million upfront payment -- with Pfizer (PFE) for use of its Matrix-M adjuvant for up to two disease areas.

Read More
image for news Novavax Stock Pops After Pfizer Licensing Agreement
Which Pharma Stock Stands Taller Right Now: LLY or PFE?
LLY, PFE
Published: January 20, 2026 by: Zacks Investment Research
Sentiment: Positive

Eli Lilly's Mounjaro and Zepbound fuel rapid growth as new launches and an oral GLP-1 near approval shape its investment case against peers.

Read More
image for news Which Pharma Stock Stands Taller Right Now: LLY or PFE?
MoneyShow's Best Investment Ideas For 2026: Part 7
PFE, PLD, PLG, PM, QUIK, RCAT, RGCCF
Published: January 19, 2026 by: Seeking Alpha
Sentiment: Neutral

MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 7 of this series includes Pfizer, Philip Morris International, Platinum Group Metals, Prologis and QuickLogic Corp.

Read More
image for news MoneyShow's Best Investment Ideas For 2026: Part 7
What to Expect From Pfizer's Non-Oncology Business in Q4?
PFE
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive

PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.

Read More
image for news What to Expect From Pfizer's Non-Oncology Business in Q4?
Pfizer: Rebound Has Just Started
PFE
Published: January 16, 2026 by: Seeking Alpha
Sentiment: Positive

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial stability, reinforcing confidence in PFE's outlook. PFE's substantial 6.7% forward dividend yield appears secure, offering attractive income in a volatile market.

Read More
image for news Pfizer: Rebound Has Just Started
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PFE
Published: January 12, 2026 by: Seeking Alpha
Sentiment: Neutral

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Read More
image for news Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Healthy Returns: What to expect from pharma at the JPM conference
AMGN, AZN, BMY, LLY, MRK, NVO, PFE
Published: January 09, 2026 by: CNBC
Sentiment: Positive

At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.

Read More
image for news Healthy Returns: What to expect from pharma at the JPM conference
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
PFE
Published: January 06, 2026 by: Zacks Investment Research
Sentiment: Positive

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
These 3 Stocks Trade at Discounts the Market Won't Ignore Forever
CMCSA, MU, PFE
Published: January 05, 2026 by: MarketBeat
Sentiment: Positive

The S&P 500 wrapped up 2025 with a total return of about 18%, the third straight year above historical norms but a lower figure than the gangbusters 25% returns of 2023 and 2024. AI euphoria is still the strongest market trend entering 2026, and the usual suspects like NVIDIA Corp. NASDAQ: NVDA and Alphabet Inc. NASDAQ: GOOGL are up once again on the first day of trading.

Read More
image for news These 3 Stocks Trade at Discounts the Market Won't Ignore Forever
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
PFE
Published: January 05, 2026 by: Business Wire
Sentiment: Neutral

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.

Read More
image for news Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer 2026: The Reset Year
PFE
Published: January 02, 2026 by: Seeking Alpha
Sentiment: Negative

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition immediately delivers advanced-stage obesity assets, strengthening PFE's competitive positioning in a high-growth market. Management plans to advance roughly 15 programs in 2026, supported by elevated R&D spending of $10.5–$11.5 billion.

Read More
image for news Pfizer 2026: The Reset Year
Investing $122,100 in These 3 High-Yield Dividend Stocks Could Make You $10,000 in Reliable Passive Income in 2026
ARCC, ET, PFE
Published: January 01, 2026 by: The Motley Fool
Sentiment: Positive

Ares Capital offers an especially juicy dividend. Energy Transfer has an impressive track record of increasing its distribution each quarter.

Read More
image for news Investing $122,100 in These 3 High-Yield Dividend Stocks Could Make You $10,000 in Reliable Passive Income in 2026
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
PFE
Published: December 31, 2025 by: MarketBeat
Sentiment: Negative

The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold.

Read More
image for news Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
3 ultra-high-yield stocks to consider for $300 of dividend income in 2026
AGNC, PFE, PFLT
Published: December 31, 2025 by: Invezz
Sentiment: Positive

Generating meaningful dividend income from modest capital requires disciplined stock selection and a clear mathematical framework. An allocation of $2,670 distributed equally across three carefully vetted ultra-high-yield securities, each offering yields exceeding 6%, can reasonably generate approximately $300 in annual dividend income.

Read More
image for news 3 ultra-high-yield stocks to consider for $300 of dividend income in 2026
Jim Cramer Names His Favorite Dividend Stocks
ENB, O, PFE
Published: December 29, 2025 by: 24/7 Wall Street
Sentiment: Positive

Jim Cramer has built a strong reputation in the industry. He's the Mad Money host who carefully picks growth stocks that have the potential to survive market ups and downs.

Read More
image for news Jim Cramer Names His Favorite Dividend Stocks
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
PFE
Published: December 26, 2025 by: Zacks Investment Research
Sentiment: Positive

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
3 Under-The-Radar Dividend Stocks to Buy on the Cheap
CPB, GIS, PFE
Published: December 24, 2025 by: 24/7 Wall Street
Sentiment: Neutral

Dividend stocks have been under pressure in the past few years due to the broader economy's unpredictable swings.

Read More
image for news 3 Under-The-Radar Dividend Stocks to Buy on the Cheap
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
PFE
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Negative

In the latest trading session, Pfizer (PFE) closed at $24.88, marking a -1.31% move from the previous day.

Read More
image for news Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade

About Pfizer Inc. (PFE)

  • IPO Date 1972-06-01
  • Website https://www.pfizer.com
  • Industry Drug Manufacturers - General
  • CEO Albert Bourla
  • Employees 81000

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.